IMPORTANCE Primary care clinicians, who are increasingly responsible for caring for the growing population of cancer survivors, may be unfamiliar with appropriate cancer surveillance strategies. Clinical practice guidelines can inform cancer follow-up care and surveillance testing. Vague recommendations and inconsistencies among guidelines can lead to overuse and underuse of health care resources and have a negative impact on cost and quality of survivorship care.
primary disease and time since treatment, surveillance modalities can include medical history and physical examinations, tumor markers, direct visualization with endoscopic procedures, and radioraphic imaging.
Given a growing shortage of oncologists in the United States, 5 survivorship care is increasingly provided by primary care physicians (PCPs). 6,7 However, PCPs infrequently receive guidance from oncologists regarding appropriate surveillance care 4 and may lack knowledge and confidence in this area. 8 To provide optimal survivorship care, PCPs 9 and professional organizations 6 have acknowledged the need for clinical practice guidelines with clear recommendations addressing the care of cancer survivors. Given the size of this patient population, their potential vulnerability, and the high cost of some tests used for surveillance testing (eg, positron emission tomographic [PET] scanning), high-quality guidelines in the area of cancer survivorship have the potential to have a great impact on value, by both improving clinical outcomes and controlling costs. In other clinical settings, guidelines have been criticized for vagueness of recommendations 10 and inconsistency, 11 limiting their applicability and usefulness to clinicians for determining appropriate care. To our knowledge, characteristics of guidelines related to the care of cancer survivors have not been previously described. We sought to evaluate the specificity of national guidelines containing recommendations about surveillance testing in survivors and to analyze the consistency of recommendations across guidelines addressing the same cancer.
Methods
We performed a cross-sectional analysis of clinical practice guidelines from North America and Europe addressing cancers with the highest estimated number of survivors in the United States as identified by the American Cancer Society. 2 We included 9 cancers (breast, colorectal, non-small-cell lung, prostate, melanoma, uterine corpus, bladder, thyroid, and testicular), which represented 73% of all cancer survivors (10 623 240 people) in the United States in 2014. 2 
Data Sources
We performed an online search for publicly available cancer guidelines for each selected cancer; searches were performed by 2 investigators (R.P.M. and R.Y. 
Surveillance Strategies
We categorized methods of surveillance as history and physical examination, tumor marker, diagnostic procedure (eg, colonoscopy), or imaging. We included any surveillance modality that was addressed by at least 1 guideline. One of 3 clinicians (R.P.M., D.K., or S.S.B.) classified each recommendation as 1 of the following: (1) risk-based recommendation, (2) recommendation for surveillance, (3) addressed but no clear recommendation provided, (4) recommendation against, or (5) cases in which surveillance was not addressed. We defined risk-based recommendations as those in which the use of a mechanism of surveillance differed based on the level of risk of recurrence. If the clinician was unsure how to classify a recommendation, it was reviewed by 1 or both of the others and consensus was reached.
Clinical Practice Guideline Specificity and Consistency testing every 3 months), the presence of a definitive stop date (eg, tumor marker testing every 3 months for 1 year), and the presence of ambiguity (ie, without a clear recommendation for or against any given test). To evaluate for consistency regarding the same surveillance method for the same cancer, we compared testing recommendations among guidelines addressing the same cancer type. We defined inconsistent guidelines when recommendations did not agree, including when one guideline recommended for or against a test while another discussed a test without a clear recommendation or did not discuss that test at all.
Statistical Analysis
We used descriptive statistics to characterize surveillance methods, recommendation types, specificity, and consistency, and used χ 2 tests to evaluate associations between guideline sources and recommendation characteristics. Owing to small sample size, we did not perform multivariable analysis.
Significance was set at P = .05, and all tests were 2-sided. All statistical analysis was performed using SAS software (version 9.4; SAS Institute Inc).
Results
We identified a total of 41 guidelines addressing posttreatment surveillance across the 9 cancer types ( Table 1) . The number of guidelines per cancer type ranged from 3 to 6 per cancer, and a total of 22 specific testing modalities were addressed. Thirty-five guidelines (85%) were from professional organizations, of which 25 (71%) were developed by national societies. Twenty guidelines (49%) were from North America, and most guidelines were published between 2014 and 2016 (66% (Table 1) . A recommendation against use was included in at least 1 guideline for 12 of 22 total testing modalities identified, although no test was recommended against consistently. Recommendations for surveillance testing varied by cancer type and sometimes across guidelines addressing the same cancer type. Some testing modalities were universally recommended across guidelines for a specific cancer type, including mammography in breast cancer, colonoscopy and tumor markers in colorectal cancer, tumor markers in prostate cancer, and ultrasonography and tumor markers in thyroid cancer.
Recommendations regarding other surveillance modalities were less consistent. With regard to tumor markers, 2 of 4 testicular cancer guidelines (50%) and 1 of 4 melanoma guidelines (25%) recommended risk-based tumor marker testing; 2 of 6 breast cancer guidelines (33%) and 1 of 5 lung cancer guidelines (20%) recommended against tumor marker testing ( Figure 1) . The tests that were most commonly recommended against were CT imaging in uterine cancer (67% of relevant guidelines) and bone scans in prostate cancer (33%) ( Table 2) .
Positron emission tomographic imaging was recommended by only 1 of 41 guidelines; this was for bladder cancer ( Figure 2 ). The remainder of guidelines either recommended against or did not address routine PET imaging. Uterine cancer had the most guidelines recommending against the use of PET imaging (67%) followed by lung cancer (60%). The cancer types with the most guidelines with ambiguous recommendations for PET scans were bladder (83%), prostate (83%), and breast (67%) cancers.
Testing frequency was provided for most of the surveillance modalities addressed (range, 88%-92%), but stop times were infrequently provided (range, 31%-38%). There was no statistically significant difference in testing frequency, inclusion of a stop time, presence of a risk-based recommendation, recommendation against at least 1 test, or guideline ambiguity by organization type or year of publication. However, there was significant variation in the presence of a stop time recommendation by cancer type (range, 0% for prostate, uterine, and thyroid cancers to 100% for colorectal cancer; P < .01). In addition, European guidelines were more likely than North American guidelines to contain ambiguous recommendations (100% vs 68%; P < .01) ( Table 3) .
Discussion
Clinical practice guidelines addressing cancer surveillance testing are critical tools for clinicians for optimizing care of the large and growing population of cancer survivors. Unclear or imprecise recommendations present challenges for all health care providers (eg, physicians, nurses, nurse practitioners) caring for cancer survivors. The specificity and consistency of recommendations across guidelines is particularly important because survivorship care is increasingly transitioned to clinicians with less familiarity with specific cancers. 6, 7 In this study, we found multiple guidelines from North America and Europe addressing posttreatment cancer surveillance containing recommendations that were often nonspecific and inconsistent. In fact, within the same disease, different guidelines often did not address all the same surveillance modalities, and relatively few surveillance modalities were recommended across all guidelines. Our findings are consistent with those of prior studies addressing the specificity and consistency of guideline recommendations related to both screening 10 and cancer care.
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Most surveillance recommendations included a testing frequency, but fewer than 1 in 3 provided a definitive stop time. Reasons for infrequent stop times are unclear, although there is a clear decreased risk of recurrence over time for most malignant neoplasms, and few surveillance modalities are required quality guideline recommendations can help clinicians maximize patient benefit and minimize potential harm, a lack of specificity may impede guideline adherence and contribute to either overuse or underuse of care. 68 Although underuse has been more thoroughly studied, excessive ongoing surveillance may harm patients through exposure either to direct harms of unnecessary surveillance tests or to harms of more invasive downstream procedures. 69 Much of the lack of recommendation specificity is likely driven by the low quality of evidence to inform optimal surveillance strategies in cancer survivors that we documented in our study, 70 and clearly poor evidence is a major barrier to the development of high-quality guidelines. 71 However, developers can optimize guideline usability by maintaining transparency about the strength of evidence while still making specific recommendations even in the absence of strong evidence. The Institute of Medicine has stated that guidelines should be valid, reliable, applicable, flexible, and clear, and should reflect a multidisciplinary process that can be regularly updated. 72 The guidelines in our sample fall short in many of these domains, which is not unique among oncology guidelines. 73 However, we believe that a number of simple changes to the development of cancer surveillance recommendations would improve their clarity, applicability, and, therefore, their ability to optimize patient outcomes.
First, recommendations about testing should use language that is unambiguous and includes a testing frequency with definitive start and stop intervals. 65 For example, with respect to surveillance imaging, a guideline could state that a specific test should be performed "every 6 months for the first 2 years, yearly for 3 years and should not be performed after a total of 5 years if there is no evidence of recurrence." Definitive statements such as "positron emission tomography scans should not be used for surveillance outside of a clinical trial" 23 should be encouraged and adopted. While shared decision-making with patients is critical for optimizing care and clinicians may not apply every recommendation to every patient, 74 clarity and consistency in guideline recommendations, along with transparent evidence ratings, can facilitate communication and patient understanding.
Next, cancer surveillance strategies should include recommendations that are tailored to recurrence risk. There is increasing recognition that risk-based guideline recommendations may optimize outcomes and care value, both generally 75, 76 and specifically in the setting of long-term monitoring of survivors of childhood cancer. 77 One-third of guidelines in our sample included at least 1 risk-based recommendation, although in these cases, risk was generally based on stage at diagnosis alone. Robust riskbased follow-up of adult cancer survivors should incorporate factors that are well established from randomized clinical trials and observational data, including cancer and patient characteristics (eg, stage, grade, genetic mutation status). In colorectal cancer, for example, extensive data exist outlining recurrence risk from decades of randomized clinical trials, including risk-based models, but these data are not currently incorporated into surveillance recommendations. [78] [79] [80] [81] [82] The NCCN melanoma guidelines are an example of higher-quality, risk-based recommendations 38 in which patients with stage I and II disease are followed by history and physical examinations only, while those with stage III and IV disease undergo more extensive surveillance with crosssectional imaging (eg, CT scans, magnetic resonance imaging) including PET scans. The lack of risk-based recommendations among guidelines in our sample likely reflects the limited data available to help instruct surveillance programs 60 ; indeed, most recommendations were based on low-quality evidence. Other barriers to risk-based recommendations include the inherent complexity of developing them and perhaps the perceived challenges with clinician interpretation. Nevertheless, risk-based recommendations are likely to provide a more efficient, costeffective approach to patient follow-up, and further incorporation of risk into surveillance recommendations would improve their usefulness.
Third, survivorship guideline development panels should incorporate all stakeholders, including generalist physicians, advanced practice clinicians, and patient representatives. 72 Currently, panels developing cancer guidelines are tasked Abbreviations: CR, chest radiography; CT, computed tomography; MRI, magnetic resonance imaging; RAIU, radioactive iodine uptake scan; US, ultrasonography.
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Quality of Cancer Surveillance Guidelines on survivorship care could facilitate change and allow developers to focus on improving recommendation quality.
Limitations
There are several important limitations to our study. First, we restricted our search to national cancer guidelines and excluded regional recommendations. This approach excluded provincial clinical practice guidelines in Canada, although they may be widely used and influential. 84 Nevertheless, including additional guidelines is likely to have increased the variation we found and would unlikely qualitatively change our results. Second, this study sample was small, and we were only able to evaluate the association between guideline characteristics and the specificity and consistency of recommendations using a univariable analysis. Owing to the nature of the study and the limited number of guidelines in existence, there was not an alternative methodological approach, and this would only influence the comparative analysis and not our primary findings. Third, there is inherent subjectivity in the interpretation of recommendations. However, we attempted to mitigate this issue by identifying and extracting important data elements to standardize guideline reporting and comparisons. Finally, our study is cross-sectional and offers a snapshot in the status of surveillance clinical practice guidelines up to March 1, 2016. Nevertheless, given the current state of cancer surveillance guidelines, it is unlikely that major qualitative changes will occur in the near future.
Conclusions
The number of cancer survivors is growing, and optimizing cancer surveillance is an important issue for individual patients, payers, and clinicians. Our review of 41 surveillance recommendations from clinical practice guidelines across 9 cancer types found a lack of specificity and consistency that hinders optimal patient care. As cancer guidelines are reviewed and revised, we believe developers should clarify recommendations with simple, nonambiguous, definitive language for, or against, the use of specific tests and specific recommendations based on patient risk.
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